Pharmaceutical, Biotechnology, and Medical Device companies know that innovation is key to their long-term success and competitiveness. With the cost to get one new drug to market exceeding $1 billion and sometimes taking greater than 10 years, there is little room for error. And as you might expect, “information” and intellectual property (IP) are at the core of new product development. Life Science organizations require a flexible information infrastructure that not only allows the free flow of information between global researchers, universities and research partners but also ensures that precious IP is protected, classified and tightly controlled. Adding to this challenge is the trend to outsource R&D and the ever increasing regulatory scrutiny from the FDA and other regulatory bodies. Lastly, the clinical trials phase is one of the most important stages in new product development. Since this involves human subjects, the management of clinical trials information needs to comply with HIPAA directives. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) has very specific directions and guidelines on how patient Personal Health Information (PHI) must be stored and protected. Leaking PHI whether inadvertent or malicious can result in sanctions, fines, civil suits and a negative impact on the image of the Life Sciences organization.
The Orchestria Solution for Life Sciences protects and controls information wherever it is stored or used, significantly minimizing the risks associated with uncontrolled information. Orchestria protects sensitive IP, clinical trials data and employee and customer data at the endpoint, message server, network and for data at rest. Orchestria helps Life Sciences organizations prevent data loss, ensure messaging compliance and enforce information classification and control.
